06:38 AM EDT, 09/17/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday that a late-stage study of its experimental therapy, patritumab deruxtecan, in certain patients with a type of non-small cell lung cancer, has met its primary endpoint.

The study found that patients treated with patritumab deruxtecan had a statistically significant improvement in progression-free survival compared with standard chemotherapy.

The company said overall survival data were immature during the analysis and are still being assessed.

It said it would share these findings with regulatory authorities and discuss next steps.

Patritumab deruxtecan is being jointly developed by Daiichi Sankyo and Merck ( MRK ).

Price: 118.49, Change: +0.53, Percent Change: +0.45